Clinical trials: PET/CT Imaging, open to volunteers
Primary Aldosteronism
Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism
The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism.
- Trial name
- EliXir (NCT07800858)
- Testing
- baxdrostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Queen Mary University of London
Soft Tissue Sarcoma
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
soft tissue sarcoma
- Trial name
- NCT07920835
- Testing
- 68Ga-HX01 Injection Solution
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Healthy Volunteer, Bone Alteration
Ultralow Dose PET Imaging for 18F-NaF Uptake
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection…
- Conditions
- Healthy Volunteer, Bone Alteration, Bone and Joint Cancer, Bone and Joint Infection
- Trial name
- NCT07284563
- Testing
- 18F-NaF
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Pancreatic Neoplasms, Stomach Neoplasms
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis.
- Conditions
- Pancreatic Neoplasms, Stomach Neoplasms, Bile Duct Neoplasms, Epithelial Ovarian Cancer
- Trial name
- NCT05172310
- Testing
- 68Ga-FAPI-46, PET/CT
- Where
- Sweden
- Volunteers
- 410 people
- Sponsor
- Karolinska University Hospital
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
PET / CT, Solid Tumors
Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors
Malignant tumors pose a grave threat to human health and impose a substantial burden on society. Molecular imaging, which enables non-invasive, in vivo visualization of biological processes at the molecular level, is crucial for…
- Conditions
- PET / CT, Solid Tumors, Adult
- Trial name
- NCT07385950
- Testing
- PET/CT Imaging with αvβ6/FAP-targeted tracer
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhongnan Hospital
RCC, Renal Cell Cancer
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included.
- Trial name
- NCT06769893
- Testing
- 68Ga-NOTA-RCCB6 PET/CT Scan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Idiopathic Parkinson Disease
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
This is a single-center, prospective observational study of patients with moderate-to-advanced primary Parkinson's disease (PD). PD is the second most common neurodegenerative disease.
- Trial name
- PD (NCT07919262)
- Testing
- Brain PET Examination, Clinical assessment, blood sampling and brain PET examination
- Volunteers
- 36 people
- Sponsor
- Xuanwu Hospital, Beijing
Lung Cancer
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
PET/CT imaging and clinical information (age, gender, smoking history, family history of cancer, history of present illness, and several tumor biomarkers, etc.) were used to establish a hierarchical multi-modal AI framework for…
- Trial name
- NCT07463300
- Testing
- PET imaging analysis, data mining, and AI model developing
- Where
- 9 sites in China
- Volunteers
- 5,500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON…
- Trial name
- NCT06750419
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 8 sites in China
- Volunteers
- 82 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL.
- Trial name
- NCT06723665
- Testing
- 18F-PSMA-1007, 18F-FDG
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Nasopharyngeal Cancinoma (NPC), Distant Metastasis
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
An AI model was developed to predict the likelihood of distant metastasis in patients with nasopharyngeal cancer based on pathology slides and MRI scans of the primary tumor.
- Trial name
- NCT06831357
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Large Vessel Vasculitis, Takayasu Arteritis
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are…
- Conditions
- Large Vessel Vasculitis, Takayasu Arteritis, Giant Cell Arteritis (GCA)
- Trial name
- LAVA-FLOW (NCT07628075)
- Testing
- [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram
- Where
- 3 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Imperial College London
B7H3, CD276 Affibody
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
Based on [68Ga]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression.
- Conditions
- B7H3, CD276 Affibody, PET/CT Imaing
- Trial name
- NCT06454955
- Testing
- [68Ga] B7H3 Affibody-BCH
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
Giant Cell Arteritis, Polymyalgia Rheumatica
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR).
- Trial name
- GCAIO (NCT06460142)
- Testing
- Aortic/ cardiac magnetic resonance imaging, Vascular ultrasound, Transorbital Ultrasound
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Prostate Cancer
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
- Trial name
- NCT06922903
- Testing
- INR101
- Where
- 32 sites in China
- Volunteers
- 240 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Aggressive Lymphoma
Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma
This multicenter study aims to evaluate the predictive value of tumor microenvironment PET/CT imaging for treatment response and prognosis in patients with aggressive lymphoma.
- Trial name
- NCT07657494
- Testing
- Al18F-NOTA-FAPI, Al18F-NOTA-grazytracer/68Ga-grazytracer
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease.
- Conditions
- Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities, Malignant Tumor
- Trial name
- NCT07400224
- Testing
- Al18F-NOTA-FAPI PET/CT(or PET/MRI)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
High-risk Prostate Cancer
Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.
Recent evidence suggests that both standard-time and delayed-time [⁶⁸Ga]Ga-PSMA PET acquisitions can reveal clinically relevant findings, and neither phase should be excluded a priori in routine practice.
- Trial name
- SPIR202302 (NCT07357259)
- Testing
- Intervention Group
- Where
- Italy
- Volunteers
- 244 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna